Loading patent…
AssigneeAbbVie Biotechnology Ltd.
InventorsRebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
Estimating the term…
Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
A multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising:
A kit for the treatment of a disorder in which TNFα activity is detrimental comprising:
A method of treating Crohn's disease in a subject comprising administering to the subject a TNFα inhibitor such that a mean serum TNFα inhibitor trough level of about 12 μg/mL is achieved.
An article of manufacture comprising a TNFα inhibitor and a package insert, wherein the package insert indicates that in patients with Crohn's disease a loading dose at week 0 followed by a second dose which is about 40-60% of the loading dose on week 2 achieves a mean serum TNFα inhibitor trough level of approximately 12 μg/mL at week 2 and week 4.
Dependencies are inferred from the claim text.